Selective inactivation of NADPH oxidase 2 causes regression of vascularization and the size and stability of atherosclerotic plaques

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 469-475

  Quesada, I M ^a   Lucero, A ^a   Amaya, C ^b   Meijles, D N ^c   Cifuentes, M E ^c   Pagano, P J ^c   Castro, C ^a  

^a UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Oxidative stress; Vascular Nox; Vulnerable plaque

Indexed keywords

APOLIPOPROTEIN E; GELATINASE B; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; VASCULOTROPIN; CYBB PROTEIN, MOUSE; CYTOCHROME C; CYTOKINE; ENZYME INHIBITOR; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MEMBRANE PROTEIN; MMP9 PROTEIN, MOUSE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, MOUSE; OXIDIZING AGENT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; ENZYME INACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; LIPID DIET; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; C57BL MOUSE; CHEMISTRY; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; REGRESSION ANALYSIS;

ANIMALS; AORTA; APOLIPOPROTEINS E; CAROTID ARTERIES; CYTOCHROMES C; CYTOKINES; DIET, HIGH-FAT; DISEASE PROGRESSION; ENZYME INHIBITORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH OXIDASE; NEOVASCULARIZATION, PATHOLOGIC; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDANTS; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; REACTIVE OXYGEN SPECIES; REGRESSION ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939817635     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.011     Document Type: Article

References (43)

1. Rosenfeld M.E. Inflammation and atherosclerosis: direct versus indirect mechanisms. Curr. Opin. Pharmacol. 2013, 13(2):154-160.
2. Legein B., Temmerman L., Biessen E.A., Lutgens E. Inflammation and immune system interactions in atherosclerosis. Cell Mol. Life Sci. 2013, 70(20):3847-3869.
3. Watanabe M., Sangawa A., Sasaki Y., Yamashita M., Tanaka-Shintani M., Shintaku M., Ishikawa Y. Distribution of inflammatory cells in adventitia changed with advancing atherosclerosis of human coronary artery. J. Atheroscler. Thromb. 2007, 14(6):325-331.
4. Hu Y., Zhang Z., Torsney E., Afzal A.R., Davison F., Metzler B., Xu Q. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J. Clin. Invest. 2004, 113(9):1258-1265.
5. Mulligan-Kehoe M.J. The vasa vasorum in diseased and nondiseased arteries. Am. J. Physiol. Heart Circ. Physiol. 2010, 298(2):H295-H305.
6. Doyle B., Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J. Am. Coll. Cardiol. 2007, 49(21):2073-2080.
7. Ritman E.L., Lerman A. The dynamic vasa vasorum. Cardiovasc. Res. 2007, 75(4):649-658.
8. Guzik B., Sagan A., Ludew D., Mrowiecki W., Chwala M., Bujak-Gizycka B., Filip G., Grudzien G., Kapelak B., Zmudka K., Mrowiecki T., Sadowski J., Korbut R., Guzik T.J. Mechanisms of oxidative stress in human aortic aneurysms - Association with clinical risk factors for atherosclerosis and disease severity. Int J Cardiol 2013 Oct 3, 168(3):2389-2396. 10.1016/j.ijcard.2013.01.278.
9. Zampetaki A., Dudek K., Mayr M. Oxidative Stress in atherosclerosis: The Role of microRNAs in Arterial Remodelling. Free Radic Biol Med 2013 Sep, 64:69-77. 10.1016/j.freeradbiomed.2013.06.025.
10. Violi F., Basili S., Nigro C., Pignatelli P. Role of NADPH oxidase in atherosclerosis. Future Cardiol. 2009, 5(1):83-92.
11. Uno K., Nicholls S.J. Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomark. Med. 2010, 4(3):361-373.
12. Hulsmans M., Holvoet P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J. Cell. Mol. Med. 2010, 14(1-2):70-78.
13. Kostyuk V.A., Potapovich A.I., Suhan T.O., de Luca C., Korkina L.G. Antioxidant and signal modulation properties of plant polyphenols in controlling vascular inflammation. Eur. J. Pharmacol. 2011, 658(2-3):248-256.
14. Liu Y., Yue Q., Belcik T., Xie A., Inaba Y., McCarty O.J., Tormoen G.W., Zhao Y., Ruggeri Z.M., Kaufmann B.A., Lindner J.R. Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ. Cardiovasc. Imaging 2013, 6(1):74-82.
15. Barry-Lane P.A., Patterson C., van der Merwe M., Hu Z., Holland S.M., Yeh E.T., Runge M.S. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J. Clin. Invest. 2001, 108(10):1513-1522.
16. Rodino-Janeiro B.K., Paradela-Dobarro B., Castineiras-Landeira M.I., Raposeiras-Roubin S., Gonzalez-Juanatey J.R., Alvarez E. Current status of NADPH oxidase research in cardiovascular pharmacology. Vasc. Health Risk Manag. 2013, 9:401-428.
17. Csanyi G., Cifuentes-Pagano E., Al Ghouleh I., Ranayhossaini D.J., Egana L., Lopes L.R., Jackson H.M., Kelley E.E., Pagano P.J. Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. Free Radic. Biol. Med. 2011, 51(6):1116-1125.
18. Rey F.E., Cifuentes M.E., Kiarash A., Quinn M.T., Pagano P.J. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ. Res. 2001, 89(5):408-414.
19. Jacobson G.M., Dourron H.M., Liu J., Carretero O.A., Reddy D.J., Andrzejewski T., Pagano P.J. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ. Res. 2003, 92(6):637-643.
20. Liu J., Yang F., Yang X.P., Jankowski M., Pagano P.J. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler. Thromb. Vasc. Biol. 2003, 23(5):776-782.
21. Touyz R.M., Chen X., Tabet F., Yao G., He G., Quinn M.T., Pagano P.J., Schiffrin E.L. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 2002, 90(11):1205-1213.
22. Molshanski-Mor S., Mizrahi A., Ugolev Y., Dahan I., Berdichevsky Y., Pick E. Cell-free assays: the reductionist approach to the study of NADPH oxidase assembly, or "all you wanted to know about cell-free assays but did not dare to ask". Methods Mol. Biol. 2007, 412:385-428.
23. Cannizzo B., Quesada I., Militello R., Amaya C., Miatello R., Cruzado M., Castro C. Tempol attenuates atherosclerosis associated with metabolic syndrome via decreased vascular inflammation and NADPH-2 oxidase expression. Free Radic. Res. 2014, 48(5):526-533.
24. Snoek-van Beurden P.A., Von den Hoff J.W. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. BioTechniques 2005, 38(1):73-83.
25. Adya R., Tan B.K., Punn A., Chen J., Randeva H.S. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 2008, 78(2):356-365.
26. Violi F., Pignatelli P., Pignata C., Plebani A., Rossi P., Sanguigni V., Carnevale R., Soresina A., Finocchi A., Cirillo E., et al. Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2013, 33(2):406-412.
27. Violi F., Sanguigni V., Carnevale R., Plebani A., Rossi P., Finocchi A., Pignata C., De Mattia D., Martire B., Pietrogrande M.C., et al. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 2009, 120(16):1616-1622.
28. Loffredo L., Carnevale R., Sanguigni V., Plebani A., Rossi P., Pignata C., De Mattia D., Finocchi A., Martire B., Pietrogrande M.C., et al. Does NADPH oxidase deficiency cause artery dilatation in humans?. Antioxidants Redox Signal. 2013, 18(12):1491-1496.
29. Xu S., Chamseddine A.H., Carrell S., Miller F.J. Nox4 NADPH oxidase contributes to smooth muscle cell phenotypes associated with unstable atherosclerotic plaques. Redox Biol. 2014, 2:642-650.
30. Cifuentes-Pagano E., Csanyi G., Pagano P.J. NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS. Cell Mol. Life Sci. 2012, 69(14):2315-2325.
31. Csanyi G., Yao M., Rodriguez A.I., Al Ghouleh I., Sharifi-Sanjani M., Frazziano G., Huang X., Kelley E.E., Isenberg J.S., Pagano P.J. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler. Thromb. Vasc. Biol. 2012, 32(12):2966-2973.
32. Drummond G.R., Selemidis S., Griendling K.K., Sobey C.G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 2011, 10(6):453-471.
33. Sibley C.T., Estwick T., Zavodni A., Huang C.Y., Kwan A.C., Soule B.P., Long Priel D.A., Remaley A.T., Rudman Spergel A.K., Turkbey E.B., et al. Assessment of atherosclerosis in chronic granulomatous disease. Circulation 2014, 130(23):2031-2039.
34. Jaipersad A.S., Lip G.Y., Silverman S., Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J. Am. Coll. Cardiol. 2014, 63(1):1-11.
35. Hutter R., Speidl W.S., Valdiviezo C., Sauter B., Corti R., Fuster V., Badimon J.J. Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1alpha activation: a novel aspect of angiogenesis in atherosclerosis. J. Cardiovasc. Transl. Res. 2013, 6(4):558-569.
36. Turgeon J., Haddad P., Dussault S., Groleau J., Maingrette F., Perez G., Rivard A. Protection against vascular aging in Nox2-deficient mice: impact on endothelial progenitor cells and reparative neovascularization. Atherosclerosis 2012, 223(1):122-129.
37. Papalambros E., Sigala F., Georgopoulos S., Panou N., Kavatzas N., Agapitos M., Bastounis E. Vascular endothelial growth factor and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization. Cerebrovasc. Dis. 2004, 18(2):160-165.
38. Park J.W., Kim W.H., Shin S.H., Kim J.Y., Yun M.R., Park K.J., Park H.Y. Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway. Biochimica Biophysica Acta 2011, 1813(5):763-771.
39. Sun Z., Lei H., Zhang Z. Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. Cytokine Growth Factor Rev. 2013, 24(5):433-442.
40. Dahl T.B., Yndestad A., Skjelland M., Oie E., Dahl A., Michelsen A., Damas J.K., Tunheim S.H., Ueland T., Smith C., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115(8):972-980.
41. Boyle J.J. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr. Vasc. Pharmacol. 2005, 3(1):63-68.
42. Kwon S.H., Ju S.A., Kang J.H., Kim C.S., Yoo H.M., Yu R. Chemokine Lkn-1/CCL15 enhances matrix metalloproteinase-9 release from human macrophages and macrophage-derived foam cells. Nutr. Res. Pract. 2008, 2(2):134-137.
43. Kigawa Y., Miyazaki T., Lei X.F., Nakamachi T., Oguchi T., Kim-Kaneyama J.R., Taniyama M., Tsunawaki S., Shioda S., Miyazaki A. NADPH oxidase deficiency exacerbates angiotensin II-induced abdominal aortic aneurysms in mice. Arterioscler. Thromb. Vasc. Biol. 2014, 34(11):2413-2420.